Cargando…

Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor

Respiratory transmission is the primary route of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Angiotensin I converting enzyme 2 (ACE2) is the known receptor of SARS-CoV-2 surface spike glycoprotein for entry into human cells. A recent study reported absent to low expressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahsan, Tamim, Sajib, Abu Ashfaqur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006196/ https://www.ncbi.nlm.nih.gov/pubmed/33817352 http://dx.doi.org/10.1016/j.bbrep.2021.100982

Ejemplares similares

Missense variants in the TNFA epitopes and their effects on interaction with therapeutic antibodies—in silico analysis
por: Ahsan, Tamim, et al.
Publicado: (2022)

Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness
por: Ahsan, Tamim, et al.
Publicado: (2020)

Role of the redox state of the Pirin-bound cofactor on interaction with the master regulators of inflammation and other pathways
por: Ahsan, Tamim, et al.
Publicado: (2023)

Common genetic variants and pathways in diabetes and associated complications and vulnerability of populations with different ethnic origins
por: Shoily, Sabrina Samad, et al.
Publicado: (2021)

Disparities in COVID-19 severities and casualties across ethnic groups around the globe and patterns of ACE2 and PIR variants
por: Shoily, Sabrina Samad, et al.
Publicado: (2021)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2
por: Anwaar, Muhammad U., et al.
Publicado: (2022)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
por: Fu, Wenyu, et al.
Publicado: (2020)

Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design
por: Meyer-Almes, Franz-Josef
Publicado: (2020)

Aspartame, acesulfame K and sucralose- influence on the metabolism of Escherichia coli
por: Shahriar, Shayan, et al.
Publicado: (2020)

A comprehensive in silico exploration of the impacts of missense variants on two different conformations of human pirin protein
por: Khan, Auroni Semonti, et al.
Publicado: (2022)

Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery
por: Ray, Abhik Kumar, et al.
Publicado: (2022)

Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease
por: Xu, Yunxia, et al.
Publicado: (2021)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
por: Ashour, Nada A, et al.
Publicado: (2022)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing
por: Krishnamoorthy, Pandikannan, et al.
Publicado: (2021)

Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
por: Abuo-Rahma, Gamal El-Din A., et al.
Publicado: (2020)

Effects of arsenic and heavy metals on metabolic pathways in cells of human origin: Similarities and differences
por: Fatema, Kaniz, et al.
Publicado: (2021)

TTN as a candidate gene for distal arthrogryposis type 10 pathogenesis
por: Biswas, Anik, et al.
Publicado: (2022)

Interaction of rs316019 variants of SLC22A2 with metformin and other drugs- an in silico analysis
por: Sajib, Abu Ashfaqur, et al.
Publicado: (2018)

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
por: Ahmed, Mohammad Z., et al.
Publicado: (2021)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing
por: Tristán-Flores, Fabiola E, et al.
Publicado: (2021)

Correction: Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
por: Ahmed, Mahmoud S., et al.
Publicado: (2023)

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing
por: Gordon, David E., et al.
Publicado: (2020)

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
por: Tummino, Tia A., et al.
Publicado: (2021)

Tackling SARS-CoV-2: proposed targets and repurposed drugs
por: Joshi, Siddhi, et al.
Publicado: (2020)

Anti-HIV drug repurposing against SARS-CoV-2
por: Sang, Peng, et al.
Publicado: (2020)

Applying polypharmacology approach for drug repurposing for SARS-CoV2
por: Jamir, Esther, et al.
Publicado: (2022)

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Improved and optimized drug repurposing for the SARS-CoV-2 pandemic
por: Cohen, Sarel, et al.
Publicado: (2023)

Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_571oub7pqa18ac16l2vc9al7e7